Junimin (Copper Gluconate, Manganese Gluconate, Potassium Iodide, Sodium Selenite, Zinc Gluconate)

Each mineral acts as a cofactor for specific enzymes. Copper and manganese support antioxidant enzymes, iodine is essential for thyroid hormone synthesis, selenium contributes to glutathione peroxidase activity, and zinc is required for numerous metabolic and immune functions. Together they help maintain cellular metabolism, protect against oxidative stress, and support immune competence.

The dose of Junimin is determined by the prescribing clinician based on the patient’s laboratory values, clinical condition and therapeutic goals. The healthcare professional will calculate the appropriate volume and infusion rate to safely deliver the required trace elements.

Safety data for Junimin in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after a thorough risk‑benefit assessment.

To place an order, submit an enquiry on the Junimin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Junimin delivers a balanced blend of five essential trace elements in a single intravenous formulation, which can simplify administration compared with using separate single‑element products. This combination may reduce the risk of cumulative dosing errors and provides coordinated delivery of minerals that often work synergistically in metabolic pathways.

Junimin must be stored refrigerated between 2 °C and 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Before use, inspect for particulate matter or discoloration and discard if any abnormalities are observed.

Junimin is administered intravenously by a qualified healthcare professional. The product is typically diluted in an appropriate carrier fluid and infused over a period determined by the prescribing clinician, ensuring a controlled rate to minimize infusion‑related reactions.

Serious risks include anaphylactic reactions, severe hypotension, electrolyte disturbances that could lead to cardiac arrhythmias, and acute renal dysfunction in susceptible individuals. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after infusion.

Junimin should be avoided in patients with known hypersensitivity to any of its components, those with uncontrolled thyroid disease due to iodine content, individuals receiving strong metal‑chelating agents, and patients with severe renal or hepatic impairment unless the prescriber determines that benefits outweigh the risks.